Can a simple biopsy predict who will respond to Chemo-Radiation?

NCT ID NCT02422498

First seen Mar 25, 2026 · Last updated May 08, 2026 · Updated 5 times

Summary

This study looks at whether a biopsy taken before treatment can help predict how well patients with metastatic or recurrent triple negative breast cancer will respond to a combination of cisplatin (chemotherapy) and radiation. About 49 adults with this type of breast cancer will receive the treatment and be monitored for tumor shrinkage. The goal is to see if a specific genetic marker (homologous recombination repair status) can guide future treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT/METASTATIC TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering at Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

Conditions

Explore the condition pages connected to this study.